Concurrent CDK4/6 inhibitors and breast RT show similar discontinuation rates to sequential treatment
In 87 matched pairs, CDK4/6 inhibitor discontinuation was 10.3% with concurrent RT versus 9.2% with sequential treatment.
In 87 matched pairs, CDK4/6 inhibitor discontinuation was 10.3% with concurrent RT versus 9.2% with sequential treatment.
In 57 patients with low rectal cancer, neoadjuvant chemoradiotherapy and consolidation CAPOX achieved 61.4% pathological complete response and 94.7% sphincter preservation.
In a prospective Danish cohort, physician-graded moderate-to-severe erectile dysfunction increased from 11.9% before treatment to 39.3% at three years.
A retrocrural nodal lesion regressed after 42 Gy in three fractions, with AFP normalization and no radiological disease at 15 months.
In 50 pancreatic SBRT fractions, expert recontouring identified duodenal dose-limit exceedances in two patients despite largely preserved target coverage.
On 87 verification CTs, proton plans spared heart, lung, and breast dose but showed target undercoverage in six patients versus one with VMAT.
Across 29 studies and 2,385 patients, pooled optic neuropathy prevalence was 5%, with grade 4 toxicity reported in 39 patients.
In 18 evaluable patients, papaverine combined with lung SBRT achieved 100% estimated two-year local control, with two dose-limiting toxicities.
In 57 evaluable patients, Gamma Knife thalamotomy improved tremor assessments in 84%, while 26.5% of those with clinical follow-up reported adverse effects.
Among 30 men with unfavorable-risk prostate cancer, single-fraction 24 Gy RT plus ADT produced 100% two-year biochemical control without grade ≥3 toxicity.
In PACK, one-year survival reached 78% after carbon-ion chemoradiotherapy, but progression remained frequent and no randomized comparator was available.
New ESTRO–ReCOG guidance recommends validated cumulative dose assessment and daily volumetric image guidance, prioritizing critical organs during lung reirradiation.
In 127 previously irradiated head and neck cancer patients, surgery plus IOERT achieved median survival of 20.5 months without a comparator.
Across 24 expert sessions, AI-assisted scribble editing reduced median contour refinement time by 70% while maintaining similar final contour quality.
Across 69 studies of late urinary toxicity after pelvic RT, hyperbaric oxygen had the strongest evidence for radiation cystitis; surgical outcomes remained heterogeneous.